About this episode

This episode explores the approval and marketing of BiDil, a drug for congestive heart failure specifically for Black patients.

How did a drug for congestive heart failure get approved and marketed for Black people only? A full transcript of this episode is available at https://www.nejm.org/doi/full/10.1056/NEJMp2601978.

Topics covered

• drug approval
• health disparities
• congestive heart failure
• racial medicine
• pharmaceutical marketing

Keywords

• BiDil
• congestive heart failure
• Black patients
• drug approval
• health disparities

Mentioned in this episode

Organizations: NEJM Group

Products: BiDil

Places: Black

More episodes of Intention to Treat

• The Attack on Equity in Medicine · June 24, 2026 · 28 min
• Is Change Possible? · June 17, 2026 · 24 min
• The Myth of Race and Genetics · June 10, 2026 · 27 min
• When Race Matters · May 27, 2026 · 27 min
• Money and Misdiagnosis · May 20, 2026 · 24 min
• How Did Race Get Into Lung Testing? · May 13, 2026 · 31 min

Explore listener stats, chart rankings, contacts and more on the Intention to Treat podcast page.